康乃德生物医药:数据监测委员会报告Seabreeze Stat研究无安全隐患或治疗相关严重不良事件

美股速递
Apr 23

康乃德生物医药控股有限公司宣布,其独立数据监测委员会针对Seabreeze Stat临床研究项目完成最新安全评估。评估结果显示,试验中未发现任何值得关注的安全性问题,也未出现与治疗方案相关的严重不良事件报告。这一积极进展为候选药物的后续研发进程提供了重要的安全性数据支持。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10